AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer

Osimertinib, a third-generation EGFR-TKI, has nowadays been applied to non-small cell lung cancer harboring activated EGFR mutation with or without T790M, but ultimately develop resistance to this drug. Here we report a novel mechanism of acquired resistance to osimertinib and the reversal of which...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Yuichi, Kusakabe, Daiki, Watari, Kosuke, Kawahara, Akihiko, Azuma, Koichi, Akiba, Jun, Taniguchi, Masahiko, Kuwano, Michihiko, Ono, Mayumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148303/
https://www.ncbi.nlm.nih.gov/pubmed/35643725
http://dx.doi.org/10.1038/s41598-022-12995-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148303/
https://www.ncbi.nlm.nih.gov/pubmed/35643725
http://dx.doi.org/10.1038/s41598-022-12995-8

Ejemplares similares